Orphan Disease Focus ARTHEx Biotech targets Myotonic Dystrophy Type 1 (DM1), an orphan disease with unmet medical needs, presenting a clear niche for collaborations with patient groups, contract research organizations, and clinical trial partners seeking first-in-class therapies.

RNA Therapeutics Platform The proprietary miR-modulating oligonucleotide platform enables fast, flexible development of tissue-targeted therapeutics, offering adjacent opportunities to co-develop or license programs targeting microRNA pathways in related neuromuscular diseases.

Clinical-Stage Momentum ATX-01 as a first-in-class disease-modifying approach positions ARTHEx for partnering or licensing discussions with larger biotech/pharma players aiming to expand RNA-based neuromuscular portfolios and accelerate IND to clinic timelines.

Strong Financing Backing Recent $87M Series B1 and strategic investor involvement (Bpifrance, EIC, Columbus Venture Partners) indicate robust funding and favorable validation, enabling business development teams to pursue collaborations, joint ventures, and co-funding opportunities.

Global Outreach Participation in high-profile investor conferences and a Valencia-based operation with international attention creates openings for strategic alliances with global pharma partners, contract development and manufacturing organizations, and academic collaborations to scale studies and commercialization.